MUMBAI (Reuters) - Sun Pharmaceutical Industries, India's No. 3 drugmaker by sales, expects revenue growth of 18-20 percent for the current fiscal year ending March 2014, its managing director said on Tuesday.
The Mumbai-based drugmaker plans to spend 8 billion rupees on capital expenditure and file about 25 generic drug applications for approval in the United States, Dilip Shanghvi said during a conference call.
Sun Pharma earlier reported a 23.4 percent rise in net profit during the fourth-quarter ended March to 10.12 billion rupees.
(Reporting by Kaustubh Kulkarni; Editing by Anand Basu)